Quantcast
Home > Quotes > CEMI
CEMI

Chembio Diagnostics, Inc. Common Stock (CEMI) Quote & Summary Data

$7.54
*  
0.16
2.08%
Get CEMI Alerts
*Delayed - data as of May 21, 2019  -  Find a broker to begin trading CEMI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CEMI After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 7.51 / $ 7.54
1 Year Target
11.25
Today's High / Low
$ 7.7783 / $ 7.50
Share Volume
22,792
50 Day Avg. Daily Volume
79,996
Previous Close
$ 7.70
52 Week High / Low
$ 11.55 / $ 4.85
Market Cap
129,435,101
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.62

Intraday Chart

Shares Traded

Share Volume:
22,792
50 Day Avg. Daily Volume:
79,996

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.65

Trading Range

The current last sale of $7.54 is 55.46% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 7.7783 $ 11.55
 Low: $ 7.50 $ 4.85

Company Description (as filed with the SEC)

We are a leading provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. We have been expanding our product portfolio based upon our proprietary Dual Path Platform, which we refer to as the DPP technology platform, which uses a small drop of blood from the fingertip to provide high-quality, cost-effective diagnostic results in approximately 15 minutes. We seek to build additional revenue streams by entering into technology collaborations with leading global healthcare companies to leverage the DPP platform. Compared with traditional lateral flow technology, the DPP technology platform provides enhanced sensitivity and specificity, advanced multiplexing capabilities, and, when used with the DPP Micro Reader, quantitative results. Our DPP test for human immunodeficiency virus, or HIV, provides sensitivity of 99.8% and specificity of 100%, and has been approved by the U.S.  ... More ...  



Risk Grade

Where does CEMI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.70
Open Date:
May 21, 2019
Close Price:
$ 7.70
Close Date:
May 20, 2019


Consensus Recommendation

Analyst Info